Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Share-based Compensation (2016 - 2025)

Ocular Therapeutix has reported Share-based Compensation over the past 13 years, most recently at $11.4 million for Q4 2025.

  • Quarterly results put Share-based Compensation at $11.4 million for Q4 2025, up 57.83% from a year ago — trailing twelve months through Dec 2025 was $43.2 million (up 30.43% YoY), and the annual figure for FY2025 was $43.2 million, up 30.43%.
  • Share-based Compensation for Q4 2025 was $11.4 million at Ocular Therapeutix, down from $11.7 million in the prior quarter.
  • Over the last five years, Share-based Compensation for OCUL hit a ceiling of $11.7 million in Q3 2025 and a floor of $3.1 million in Q1 2021.
  • Median Share-based Compensation over the past 5 years was $4.5 million (2023), compared with a mean of $6.3 million.
  • Biggest five-year swings in Share-based Compensation: skyrocketed 155.9% in 2024 and later fell 14.3% in 2025.
  • Ocular Therapeutix's Share-based Compensation stood at $3.8 million in 2021, then increased by 10.2% to $4.2 million in 2022, then rose by 2.22% to $4.3 million in 2023, then soared by 66.29% to $7.2 million in 2024, then soared by 57.83% to $11.4 million in 2025.
  • The last three reported values for Share-based Compensation were $11.4 million (Q4 2025), $11.7 million (Q3 2025), and $9.7 million (Q2 2025) per Business Quant data.